Page 51 - GALENIKA MEDICAL JOURNAL

9. Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical- 34. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB.
immunological update. J Neurol. 2016 Apr;263(4):826-34. Retrospective analysis of the use of cyclosporine in
myasthenia gravis. Neurology. 2000;55:448-50.
10. Koneczny I, Cossins J, Vincent A. The role of musclespecific
tyrosine kinase (MuSK) and mystery of MuSK myasthenia 35. Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I,
gravis. J Anat. 2014 Jan; 224(1):29-35. Pavlovic S, et al. Cyclosporine in the treatment of myasthenia
gravis. Acta Neurol Scand. 2005 Apr;111(4):247-52.
11. Kim N, Steigler AL, Cameron TO, Hallock PT, Gomez AM,
Huang JH, et al. Lrp4 is a receptor for agrin and forms a 36. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Factors
complex with MuSK. Cell. 2008 Oct;135(2):334-42. associated with response to calcineurin inhibitors in
myasthenia gravis. Muscle Nerve. 2010 Feb;41(2):212-8.
12. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves
as a coreceptor of agrin. Neuron. 2008 Oct 23;60(2):285-97. 37. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH,
et al. An international, phase III, randomized trial of mycophenolate
13. Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, mofetil in myasthenia gravis. Neurology. 2008 Aug 5;71(6):400-6.
Graus F, et al. The expanding field of IgG4-mediated neurological
autoimmune disorders. Eur J Neurol. 2015 Aug;22(8):1151-61. 38. Meriggioli MN, Rowin J, Richman JG, Leurgans S.
Mycophenolate mofetil for myasthenia gravis: a double-blind,
14. Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep;998:494-9.
F, Evoli A. Anti-MuSK antibodies: correlation with myasthenia
gravis severity. Neurology. 2006 Aug;8:67(3):505-7. 39. Cruz JL, Wolff ML, Vanderman AJ, Brown JN.The emerging
role of tacrolimus in myasthenia gravis.
15. Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR,
Wirtz PW, et al. Clinical fluctuations in MuSK myasthenia 40. Ther Adv Neurol Disord. 2015 Mar;8(2):92-103.
gravis are related to antigen-specific IgG4 instead of
IgG1. J Neuroimmunol. 2008 Mar;195(1–2):151-6. 41. Duan W, Peng Y, Jin W, Ouyang S, Yang H. Tacrolimus as Single-Agent
Immunotherapy and Minimal Manifestation Status in Nonthymoma
16. Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Myasthenia Gravis. J Immunol Res. 2021 Nov 20;2021:9138548.
Detmers FJ, et al. Muscle-specific kinase myasthenia gravis
IgG4 autoantibodies cause severe neuromuscular junction 42. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC,
dysfunction in mice. Brain. 2012 Apr;135(Pt 4):1081-101. Marx A, et al. Randomized Trial of Thymectomy in
Myasthenia Gravis. N Engl J Med. 2016;375:511-22.
17. Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke
B, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody 43. Gao J, Jin C, Ao YQ, Tang J, Ding JY, Dong JH, et al. Minimmally
negative myasthenia gravis. J Neurol. 2012 Mar;259(3):427-35. invasive thymctomy for myasthenia gravis: a 7-year
retrospective study. Gland Surg. 2021 Dec;10(12):3342-50.
18. Osserman KE, Teng P, Kaplan L. Studies in myasthenia
gravis; preliminary report on therapy with mestinon 44. Samtleben W, Besinger UA, Toyka KV, Fateh-Moghadam A, Brehm
bromide. J Am Med Assoc. 1954;155:961-5. G, Gurland HJ. Plasma-separation in myasthenia gravis: a new
method of rapid plasma exchange. Klin Wochenschr. 1980;58:47-9.
19. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus
on pyridostigmine. Clin Drug Investig. 2011;31:691-701. 45. Newsom-Davis J, Vincent A, Wilson SG, Ward CD, Pinching AJ, Hawkey C.
Plasmapheresis for myasthenia gravis. N Engl J Med. 1978;298:456-7.
20. Lavrnić D. Medikamentno lečenje miastenije gravis.
U: Myasthenia gravis: Apostolski S, Lavrnić D, Djukić 46. Eienbroker C, Seitz F, Spengler A, Kurz H, Seipelt M, Sommer
P (Eds). Beograd:Vizartis, 1998; p. 141-61. N, et al. IVIg maintenance treatment in myasthenia
gravis: a randomized, controlled trial sample size
21. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. simulation. Muscle Nerve. 2014 Dec;50(6):999-1004.
International consensus guidance for management of myasthenia
gravis: executive summary. Neurology. 2016 Jul;26:87:419-25. 47. Gelfand EW.Intravenous immune globulin in autoimmune and
inflammatory diseases. N Engl J Med. 2021;367:2015-25.
22. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-
Jones D. Myasthenia gravis: association of British neurologists’ 48. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic
management guidelines. Pract Neurol. 2015 Jun;15:199-206. T, et al. Treatment of myasthenia gravis exacerbation
with intravenous immunoglobulin: a randomized double-
23. Morren J, Li Y. Maintenance immunosuppression in myasthenia blind clinical trial. Arch Neurol. 2005;62:1689-93.
gravis, an update. J Neurol Sci. 2020 Mar 15;410:116648.
49. Menn D, Barnett C, Bril V. Novel Treatments in Myasthenia
24. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid- Gravis. Front. Neurol. 2020 June 30;11:538.
induced exacerbation in myasthenia gravis. J Clin
Neurosci. 2006 Dec;13(10):1006-10. 50. Dhillon S. Eculizumab: A Review in Generalized Myasthenia Gravis.
Drugs. 2018 Mar;78(3):367-76.
25. Gotterer L, Li Y. Maintenance immunosuppression in
myasthenia gravis. J Neurol Sci. 2016 Oct 15;369:294-302. 51. Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa
I, et al. Safety and efficacy of eculizumab in anti-acetylcholine
26. Farrugia ME, Goodfellow JA. A Practical Approach to Managing receptor antibody-positive refractory generalised myasthenia
Patients With Myasthenia Gravis-Opinions and a Review gravis (REGAIN): a phase 3, randomised, double-blind, placebo-
of the Literature. Front Neurol. 2020 Jul 7;11:604. controlled, multicentre study. Lancet Neurol. 2017 Dec;16(12):976-86.
27. Lorenzoni PJ, Kay CSK, Zanlorenzi MF, Ducci RD, Werneck LC, 52. Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, et al.
Scola RH. Myasthenia gravis and azathioprine treatment: Safety, efficacy, and tolerability of efgartigimod in patients with
adverse events related to thiopurine S-methyltransferase generalised myasthenia gravis (ADAPT): a multicentre, randomised,
(TPMT) polymorphisms. J Neurol Sci. 2020;412:116734. placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526-36.
28. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli 53. Tandan R, Hehir MK 2nd, Waheed W, Howard DB.
A, et al. International Consensus Guidance for Management of Rituximab treatment of myasthenia gravis: A systematic
Myasthenia Gravis: 2020 Update. Neurology. 2021 Jan 19;96(3):114-22. review. Muscle Nerve. 2017 Aug;56(2):185-96.
29. Goulon M, Elkharrat D, Lokiec F, Gajdos P. Results of a one-year 54. Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press
open trial of cyclosporine in ten patients with severe myasthenia R, Piehl F. Comparison Between Rituximab Treatment for
gravis. Transplant Proc. 1988 Jun;20(3 Suppl 4):211-7. New-Onset Generalized Myasthenia Gravis and Refractory
Generalized Myasthenia Gravis. JAMA Neurol. 2020 Aug 1;77(8):974-81.
30. Russell G, Graveley R, Seid J, al-Humidan AK, Skjodt H.Semin.
Mechanisms of action of cyclosporine and effects on connective
tissues. Arthritis Rheum. 1992 Jun;21(6 Suppl 3):16-2.
31. Liddicoat AM, Lavelle EC. Modulation of innate immunity
by cyclosporine A. Biochem Pharmacol. 2019 May;163:472-80.
Konflikt interesa: Nema
32. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical
therapeutic trial of cyclosporine in myasthenia gravis. Primljeno: 01. 03. 2022.
Ann N Y Acad Sci. 1993 Jun 21;681:539-51.
Prihvaćeno: 20. 04. 2022.
33. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group Onlajn: 30. 06. 2022.
of severe myasthenia gravis patients. J Neurol. 1997 Sep;244(9):542-7.
REVIJALNI RADOVI Galenika Medical Journal, 2022; 1(2):44-51. 51